Infliximab is safe and induces sustained remission with complete mucosal healing in Crohn's disease in a patient with pan resistant pseudomonas cystic fibrosis: a case report.
Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland. Electronic address: gibsond@tcd.ie.
D J
DJ
Gibson
National Referral Centre for Adult Cystic Fibrosis, St. Vincent's University Hospital, Dublin, Ireland; School of Medicine and Medical Science, University College Dublin, Ireland.
C G
CG
Gallagher
Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland; School of Medicine and Medical Science, University College Dublin, Ireland.
G A
GA
Doherty
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000150:complications*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications*; D011550:Pseudomonas aeruginosa; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab
Crohn’s disease; Cystic fibrosis; Infliximab; Mucosal healing; Pseudomonas